The grades of 4 Pharmaceuticals stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

Phibro Animal Health Corporation Class A (PAHC) is seeing ratings go up from a C last week to a B this week. The company also gets A’s in operating margin growth and return on equity. For more information, get Portfolio Grader’s complete analysis of PAHC stock.

Intersect ENT Inc (XENT) gets a higher grade this week, advancing from a C last week to a B. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of XENT stock.

DURECT Corporation (DRRX) improves from a B to a A rating this week. DURECT Corporation is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. For more information, get Portfolio Grader’s complete analysis of DRRX stock.

Apricus Biosciences, Inc.’s (APRI) ratings are looking better this week, moving up to a B from last week’s C. Apricus Biosciences, Inc. engages in the research and development of pharmaceutical drugs and drug candidates based on its proprietary NexACT drug delivery technology. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of APRI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.